Anti-tnf-α compounds as a treatment for depression

Sarit Uzzan, Abed N. Azab

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations


Millions of people around the world suffer from psychiatric illnesses, causing unbearable burden and immense distress to patients and their families. Accumulating evidence suggests that inflammation may contribute to the pathophysiology of psychiatric disorders such as major depression and bipolar disorder. Copious studies have consistently shown that patients with mood disorders have increased levels of plasma tumor necrosis factor (TNF)-α. Given these findings, selective anti-TNF-α compounds were tested as a potential therapeutic strategy for mood disorders. This mini-review summarizes the results of studies that examined the mood-modulating effects of anti-TNF-α drugs.

Original languageEnglish
Article number2368
Issue number8
StatePublished - 2 Apr 2021


  • Bipolar disorder
  • Depression
  • Inflammation
  • Pentoxifylline
  • TNF-α
  • TNFR

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry


Dive into the research topics of 'Anti-tnf-α compounds as a treatment for depression'. Together they form a unique fingerprint.

Cite this